secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001171843-25-001383
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst files patent infringement lawsuit against Annora Pharma over generic ORLADEYO
--------------------------------------------------------------------------------

- Annora Pharma sought FDA approval for generic ORLADEYO, challenging three patents expiring in 2039.
- BioCryst filed suit March 10, 2025, in Delaware District Court against Annora, Hetero Labs, Hetero USA, and Camber.
- Lawsuit seeks to enjoin generic launch and order FDA approval only after 2039 patent expiry (including extensions).
- Six other ORLADEYO Orange Book patents expiring in 2035 were not challenged by Annora.
- Company intends to vigorously enforce intellectual property rights protecting ORLADEYO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325001383/0001171843-25-001383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325001383/f8k_031125.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer